TME Pharma Announces Publication of ESMO Congress 2023 Abstract on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the European Society for Medical Oncology (ESMO) has published an abstract on the ongoing NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma). The data will be presented in an oral presentation at the ESMO Congress by Dr. Julian Layer, one of the investigators of the GLORIA trial, on Saturday, October 21, 2023, starting at 11:15 a.m. CEST in Madrid, Spain.

The abstract highlights an in-depth analysis of how the combination of radiotherapy and the CXCL12 inhibitor NOX-A12 remodels the immune tumor microenvironment in newly diagnosed glioblastoma. Results from matched pre- and post-treatment analysis of tumor tissue from the GLORIA trial support the modes of action of treatment with radiotherapy and NOX-A12 (1) to counteract vasculogenesis, i.e. the de novo creation of blood vessels from bone marrow-derived cells after radiotherapy, and (2) to modulate the tumor immune microenvironment leading to proliferation and clustering of cytotoxic T cells in tumor tissue.

Details of the oral presentation at the ESMO Congress 2023 are as follows:

Title: Spatial remodeling of the immune tumor microenvironment after radiotherapy of CXCL12 inhibition in glioblastoma in the Phase 1/2 GLORIA trial
Speaker: Dr. Julian Layer, University of Bonn, Germany
Session: Mini Oral 508MO
Lecture Time and Date: 11:15-11:20 a.m. CEST, Saturday, October 21, 2023

The full abstract is available online via the ESMO Congress website and the TME Pharma website. TME Pharma will also publish the full presentation on its website at the time of the lecture on October 21.

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France, Spain and the United States. The company’s second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.